Is the New mRNA Flu Shot Better Than a Regular One?
The first mRNA seasonal flu vaccine is here. Moderna's mFlusiva is approved for adults 50 and older starting fall 2026, and if you're a healthy adult between 50 and 64, it's a defensible upgrade over your usual flu shot: about a quarter fewer lab-confirmed cases of flu, at the price of a sorer arm. If you're 65 or older, the question is trickier. Your current best options are the high-dose and adjuvanted shots, and whether mFlusiva beats those is the exact question the FDA is now making Moderna answer.
On August 5, 2026, the FDA approved mFlusiva as a single intramuscular dose for adults 50 and older, with supply expected in pharmacies for the 2026-2027 season. The platform isn't new; you already know it from the COVID shots. What's new is that this is the first mRNA flu vaccine to clear a hard clinical bar against a licensed comparator, not just a lab reading of antibodies.
What FLUENT actually measured
FLUENT randomized about 40,700 adults 50 and older across 11 countries to either mFlusiva or a licensed standard-dose flu shot. It counted PCR-confirmed flu-like illness, not antibody titers. mFlusiva cut those cases by about 27% compared with the standard shot. In absolute terms, roughly 2.0% of mFlusiva recipients got PCR-confirmed flu versus 2.8% on the standard shot. The benefit held up in the subgroup 65 and older. Results were published in the New England Journal of Medicine in May 2026.
That's the bar earlier mRNA flu candidates hadn't cleared. They could raise antibody levels. Antibody levels aren't what you care about. Not getting the flu is.
Why the comparator matters if you're 65 or older
The comparator in FLUENT was a standard-dose flu shot, the routine one most adults under 65 get. It isn't what guidelines already prefer for adults 65 and older. That group gets one of two enhanced shots, high-dose or adjuvanted (FLUAD), both built to work harder in an older immune system, and both have outperformed the standard shot in older adults in earlier trials.
FLUENT didn't test mFlusiva head-to-head against either one for clinical efficacy. The FDA handled that gap directly. It gave traditional approval only for adults 50 to 64. For adults 65 and older, it granted accelerated approval, based partly on a separate immunogenicity study comparing mFlusiva's antibody response with the high-dose vaccine.
How mFlusiva fits alongside your other options
| Vaccine | Who it's for | How it compared in trials | Approval and coverage |
|---|---|---|---|
| mFlusiva (mRNA-1010) | Adults 50 and older | About a quarter fewer PCR-confirmed flu cases than a standard shot; not tested head-to-head against high-dose or FLUAD on clinical outcomes | Full approval for 50-64; accelerated approval for 65+; Medicare Part B covers, commercial coverage this season uncertain |
| Standard-dose inactivated (egg-based) | Adults 18 and older | The comparator in FLUENT | Long-established; broadly covered |
| High-dose inactivated | Preferred for 65 and older | Better than the standard shot at preventing flu in older adults | Long-established; covered for 65+ |
| Adjuvanted (FLUAD) | Preferred for 65 and older | Stronger antibody response than the standard shot in older adults | Long-established; covered for 65+ |
A sorer shot, but nothing new on safety
mFlusiva stings more. About two-thirds of trial participants had injection-site pain, nearly half had fatigue, and roughly a third had a headache, all noticeably more common than with the standard shot. Almost all of it was mild-to-moderate and short-lived. Serious adverse events were similar between groups, 2.2% with mFlusiva versus 1.9% with the comparator. No cases of myocarditis or pericarditis turned up in the pre-specified 42-day risk window, and FDA reviewers flagged no new safety signals at approval.
Cost and coverage this fall
There's a practical wrinkle. CDC's Advisory Committee on Immunization Practices, whose recommendations usually trigger no-cost-sharing coverage under the ACA, hasn't voted on mFlusiva. Medicare Part B covers flu vaccination by statute, so a Medicare beneficiary can get mFlusiva without cost-sharing wherever it's stocked. If you're on commercial insurance, coverage this season isn't settled and may vary by plan. For adults 65 and older, that gap may decide the choice before any head-to-head data ever reports.
What to do this fall
If you're 50 to 64 and healthy, mFlusiva is a reasonable upgrade over the standard flu shot: a modest but real cut in lab-confirmed flu, for a day or two of a sorer arm. If you're 65 or older, the high-dose and adjuvanted shots remain the established standard, and whether mFlusiva beats either on clinical outcomes is the exact question the FDA is now making Moderna answer. An ACIP vote will also set where mFlusiva sits in the schedule and how it's paid for.